One patient, unusually broad changes
A case report published May 28, 2026, in Frontiers in Neuroscience describes an older Japanese-American woman who showed striking changes after taking psilocybin-containing mushrooms. The paper, written by Marcos Lago, Mariana Cerveira, and Joe Xavier Simonet of Associação Cruz de Ankh in São Paulo, Brazil, involved a woman in her 80s with a clinically diagnosed 10-year history of Alzheimer’s disease. For about five years, she had spoken mostly in single syllables, needed help walking, struggled to dress herself, had trouble swallowing, and experienced urinary incontinence. She lived under constant family and caregiver supervision. The authors also note that formal biomarker confirmation and advanced imaging were not available, so a vascular or mixed contribution could not be fully excluded.
The first dose and the overnight change
With her son’s consent, the woman received 5 grams of dried Enigma-strain Psilocybe cubensis by mouth. That was 5 grams of mushrooms, not 5 grams of purified psilocybin, a distinction that tends to vanish once a complicated medical report meets the internet. The first hours were difficult. Clinicians suspected hyperthermia after she sweated heavily and entered a prolonged deep sleep-like state. About 19 hours later, near 3:30 a.m., she woke on her own and began speaking about her life for roughly four hours. Her son reported hearing memories and reflections that she had not expressed in years. Over the next several days, her speech shifted to spontaneous conversation, urinary continence returned, and she walked without assistance by the second day. Within two to three days, she was dressing herself, recognizing family members, maintaining eye contact, smiling back, and showing more initiative. One month later, the authors reported that she remained continent and functionally better than her baseline.
A second session added more observations
A later supervised session used 3 grams. During that session, the patient was more verbally expressive, showed more facial expression and spontaneous humor, walked with greater agility, and described surfing with her son on a peaceful island. In follow-up, she was quoted as saying, ‘It is pleasant to come here.’ The report said there were no severe persistent adverse effects, prolonged agitation, significant cardiovascular instability, persistent psychosis, or delayed neurological deterioration during follow-up. Those observations are encouraging, but they remain observations from one patient, not proof that the treatment is safe or effective for people with Alzheimer’s generally.
The paper is cautious, even if headlines are not
The authors explicitly state that the findings do not imply disease reversal. They say spontaneous fluctuations in dementia cannot be ruled out, and the case lacked standardized cognitive scales, EEG testing, a sleep study, and imaging that might clarify the mechanism. Their explanation is that residual function may become reachable under certain neuromodulatory conditions, not that plaques dissolved or Alzheimer’s was cured. The report also arrives during a wider policy debate. In April 2026, President Trump signed an executive order directing the FDA to issue new guidance for clinical trials involving psilocybin, ibogaine, LSD, and MDMA, while tasking NIH with supporting additional studies, especially involving veterans and PTSD. The substances remain Schedule I outside approved research. For now, this case is a reason to study the question carefully, not a reason to skip the study.
WE’D LOVE TO HEAR YOUR THOUGHTS! PLEASE COMMENT BELOW.
Leave a Comment